The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
Boasting an excellent safety record and high success rates, daclatasvir is now approved in Europe to treat Hepatitis C.
Continue reading »Daklinza, a Bristol-Myers Squibb Inc. drug, was approved for the treatment of Hepatitis C in Japan and now in Europe as well.
Continue reading »Approved by the FDA as a medication for use in combination with peginterferon alfa and ribavirin to treat chronic Hepatitis C genotype 1 - Incivek will no longer be sold since better medications have become available.
Continue reading »Find out about Janssen's goal for Olysio to be used once-daily in combination with Sovaldi.
Continue reading »
Will cutting HCV treatment time down from 12 weeks to 4 weeks help reduce cost of this cure?
Continue reading »Find out about a new phase I clinical trial that Achillion Pharmaceuticals Inc. has initiated for its Hepatitis C drug candidate, ACH-3422.
Continue reading »SBEL1 is a Chinese herbal extract showing great potency against the Hepatitis C virus. In addition, this compound may be paving the way for integrative Hepatitis C treatment.
Continue reading »In recognition of May being Hepatitis Awareness Month, the American Liver Foundation invites you to participate in a live webinar program, Hepatitis C: Treatment Options and the Patient Experience, on Wednesday, May 28.
Continue reading »In a Phase II study conducted by Merck & Co, a 98% cure rate was achieved for previously untreated Hepatitis C patients without cirrhosis.
Continue reading »Learn about the clinical data which suggests that interferon-free regimens containing Gilead's Sovaldi (sofosbuvir) and Bristol-Myers Squibb's NS5A inhibitor daclatasvir have advantages over currently available regimens for HCV genotype-3 infections.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
